Surrozen (NASDAQ:SRZN) VP Yang Li Sells 1,584 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 1,584 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $52,794.72. Following the sale, the vice president directly owned 17,216 shares in the company, valued at approximately $573,809.28. This represents a 8.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Surrozen Price Performance

NASDAQ:SRZN opened at $32.64 on Wednesday. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $35.00. The stock has a market capitalization of $375.03 million, a PE ratio of -0.98 and a beta of 0.59. The business’s 50-day simple moving average is $28.27 and its 200-day simple moving average is $22.11.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($6.30). Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 4,055.04%. The business had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.66 million. On average, research analysts expect that Surrozen, Inc. will post -4.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Ikarian Capital LLC acquired a new position in shares of Surrozen during the 4th quarter worth about $1,487,000. Quadrature Capital Ltd acquired a new stake in shares of Surrozen in the fourth quarter valued at approximately $335,000. Millennium Management LLC lifted its position in shares of Surrozen by 557.1% in the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock valued at $16,301,000 after buying an additional 611,497 shares during the last quarter. Eversept Partners LP lifted its position in shares of Surrozen by 23.8% in the fourth quarter. Eversept Partners LP now owns 95,286 shares of the company’s stock valued at $2,153,000 after buying an additional 18,289 shares during the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in shares of Surrozen by 169.3% in the fourth quarter. Balyasny Asset Management L.P. now owns 190,489 shares of the company’s stock valued at $4,305,000 after buying an additional 119,757 shares during the last quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on SRZN. TD Cowen began coverage on Surrozen in a report on Tuesday, April 21st. They set a “buy” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a report on Tuesday, March 24th. Wall Street Zen upgraded Surrozen from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price objective (up from $32.00) on shares of Surrozen in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $38.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.